Ganymed Robotics awarded a €2.5M grant from the European Commission through the EIC Accelerator Program
Ganymed Robotics, a developer of advanced software and robotics technologies for orthopedic surgeons, today announces it has secured a €2,5 M grant through the European Innovation Council (EIC) Accelerator program. EIC funding will help Ganymed bring its innovation to the millions of patients suffering from arthritis.
EIC Accelerator, designed to develop and scale up ground-breaking innovations, is the most competitive public funding scheme for deeptech startups in the world, with this year over 2000 companies applying and only 65 winners.
Sophie Cahen, CEO of Ganymed Robotics, indicates: “We are thrilled by EIC Accelerator’s support which validates the high potential of Ganymed’s technology and comes as a strong recognition of the major milestones Ganymed has achieved so far. We are now in a solid position to accelerate the development of our unique, patented technology platform to bring more intelligence and efficiency into the operating room and become the new standard of care for joint replacement.”
Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics. Ganymed’s first application is a robotic surgical assistant for total knee arthroplasties (TKA). Driven by a growing and aging population, demand for orthopedic surgery is rapidly increasing and the market for TKA is expected to rise from 2.4 million procedures in 2021 to 5.7 million in 2030 in the OECD alone. Orthopedic surgeries are complex, yet 95% are performed without technological assistance, leading to sub-optimal outcomes; patient dissatisfaction rate is above 20%. Ganymed’s device is the first compact, ergonomic, and intuitive robot, simplifying, accelerating, and increasing the accuracy of orthopedics.
EIC Accelerator’s support comes at a pivotal time for Ganymed, following major successful milestones in R&D, intellectual property, product design and human resources.
The company launched a clinical trial in September 2021 to validate the company’s proprietary algorithms and collect unique in vivo data, enabling new opportunities for AI-assisted surgery. 50 patients already enrolled, with 36 more to come. Ganymed secured strategic partnerships with manufacturers to initiate the industrialization of its device. On the intellectual property front, the company obtained a patent in the United States and has 5 more pending patents, with more filings to come. Attesting of the medical community’s endorsement, two top international orthopedic surgeons personally invested in the company. Furthermore, Ganymed reinforced its management team through the recruitment of former Global R&D Director at ZimmerBiomet Michel Vernizeau, as Vice President of R&D.
The company will use the EIC funding to accelerate product development and further strengthen an already world-class team, to become global category leader in surgical orthopedics robotics by the end of the decade.
About Ganymed Robotics
Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopaedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 20 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopaedics indications. Ganymed Robotics won national and international innovation awards, such as I-Lab, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator.
For additional information: https://www.linkedin.com/company/ganymed-robotics/?originalSubdomain=fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014006089/en/
Contact information
Press
Anne Rein
Strategies & Image (S&I)
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv811.12.2025 15:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833. The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chr
SLB Enters Collaboration Agreement to Accelerate New Digital Solutions11.12.2025 15:28:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) signed a strategic collaboration agreement with Shell to develop digital and AI solutions that drive measurable performance and efficiency gains across upstream operations for the company and the wider industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211832051/en/ The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI infrastructure that unifies data and workflows across subsurface, well construction and production in a secure digital environment, using SLB’s Lumi™ data and AI platform. The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI i
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 15:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to-end QC to enable dataset sizes previously unattainable for most research organizations. The Tahoe project represents one of the largest sequencin
Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 15:00:00 EET | Press release
Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gbps) of uplink capacity. Starlink’s global broadband service depends on processing and routing large volumes of real-time data, including inter-satellite optical link traffic, orbital mesh routing decisions, adaptive beam steering, and the high-throughput downlink required to serve its customers. The X2 delivers 12.8 Tbps of switching capacity using state-of-the-art 100G SerDes and TSMC’s N5 process, providing a power-efficient, ultra-low-
Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 14:36:00 EET | Press release
Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are entering regulated ecosystems, and AI is transforming every layer of the value chain. Our research is a clear warning:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom